Heidelberg Pharma sees promising results in multiple myeloma trial

Lead ATAC candidate HDP-101 shows strong clinical activity and safety in phase 8 cohort

Heidelberg Pharma has reported encouraging progress in its phase 2/2a trial of HDP-101 (INN: pamlectabart tismanitin), its lead ATAC candidate for relapsed or refractory multiple myeloma.

The company confirmed that two patients in cohort 8 achieved stringent complete remission (sCR), with no detectable tumour cells in blood or bone marrow.

Seven patients were evaluated at a dose level of 140 µg/kg. All showed a favourable safety and tolerability profile, with no dose-limiting toxicities observed. Four…